Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Surmodics, Inc. SRDX NASDAQ

NASDAQ Global Select • Healthcare • Medical - Devices • US • USD

SharesGrow Score
40/100
0/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$39.50
-8.1%

Surmodics, Inc. (SRDX) is a Medical - Devices company in the Healthcare sector, currently trading at $42.98. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 0 out of 7 criteria passed.

Analyst consensus target is SRDX = $40 (-8.1% upside).

Financials: revenue is $126M, +7.6%/yr average growth. Net income is $12M (loss), growing at -433.6%/yr. Net profit margin is -9.2% (negative). Gross margin is 73.8% (+34.6 pp trend).

Balance sheet: total debt is $33M against $119M equity (Debt-to-Equity (D/E) ratio 0.28, conservative). Current ratio is 3.96 (strong liquidity). Debt-to-assets is 18.6%. Total assets: $179M.

Analyst outlook: 4 / 7 analysts rate SRDX as buy (57%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 35/100 (Fail), Growth 40/100 (Partial), Past 25/100 (Fail), Health 67/100 (Partial), Moat 64/100 (Partial), Future 38/100 (Fail), Income 10/100 (Fail).

$39.50
▼ 8.1% Downside
Average Price Target
Based on 7 Wall Street analysts offering 12-month price targets for Surmodics, Inc., the average price target is $39.50, with a high forecast of $43.00, and a low forecast of $36.00.
Highest Price Target
$43.00
Average Price Target
$39.50
Lowest Price Target
$36.00

SRDX SharesGrow Score Overview

40/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 35/100
Valuation — P/E, PEG, Forward PEG
GROWTH 40/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 64/100
Gross margin is + market cap
FUTURE 38/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SRDX

✗
VALUE Fail
35/100
SRDX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $40, implying -6.9% from the current price $43. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
40/100
SRDX: +7.6%/yr revenue is, -433.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
SRDX: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
67/100
Balance sheet SRDX: Debt-to-Equity (D/E) ratio 0.28 (conservative), Current ratio is 3.96 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
64/100
SRDX: Gross margin is 73.8% (+34.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 64/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
38/100
Analyst outlook: 4 / 7 analysts rate SRDX as buy (57%). Analyst consensus target is $40 (-6.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
SRDX: Net profit margin is -9.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range25.87-43.0048
Volume5.34M
Avg Volume (30D)435.96K
Market Cap$614.51M
Beta (1Y)1.39
Share Statistics
EPS (TTM)-0.82
Shares Outstanding$14.15M
IPO Date1998-03-04
Employees389
CEOGary R. Maharaj
Financial Highlights & Ratios
Revenue (TTM)$126.08M
Gross Profit$93.05M
EBITDA$4.73M
Net Income$-11.54M
Operating Income$-5.65M
Total Cash$40.11M
Total Debt$33.24M
Net Debt$-2.87M
Total Assets$178.56M
Price / Earnings (P/E)-52.4
Price / Sales (P/S)4.87
Analyst Forecast
1Y Price Target$39.50
Target High$43.00
Target Low$36.00
Upside-8.1%
Rating ConsensusBuy
Analysts Covering7
Buy 57% Hold 29% Sell 14%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS8688731004

Price Chart

Track all markets on TradingView
SRDX
Surmodics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Medical - Devices
25.87 52WK RANGE 43.00

People Also View

LIVN
LIVN
LivaNova PLC
$64.99
+0.63%
 ITGR
ITGR
Integer Holdings Corporation
$88.63
+1.03%
 NUVA
NUVA
NuVasive, Inc.
$39.75
-2.24%
 AXGN
AXGN
AxoGen, Inc.
$34.46
+2.96%
 CNMD
CNMD
CONMED Corporation
$39.73
+3.30%
 FNA
FNA
Paragon 28, Inc.
$13.09
+0.00%
 SIBN
SIBN
SI-BONE, Inc.
$14.43
+3.07%
 NPCE
NPCE
NeuroPace, Inc.
$15.35
+3.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message